Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

18. august 2026 oppdatert av: AFT Pharmaceuticals, Ltd.

A Multicentre, Prospective, Randomized, Active-Controlled, Open-Label, Phase III Study to Test the Non-Inferiority of Intravenous Injection of Ferric Bepectate IV Injection Compared to Ferric Carboxymaltose for Treatment of Patients With Iron Deficiency Anaemia (IDA)

The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established formulation (Ferric carboxymaltose). It will also learn about the safety of Ferric Bepectate IV Injection. The main questions it aims to answer are:

  • Does hemoglobin increase by the same amount 6 weeks after each treatment?
  • What medical problems do participants have when being treated with the drug? Researchers will compare single dose treatment plans of Ferric Bepectate to double dose treatment plans of both Ferric Bepectate and Ferric carboxymaltose.

Participants and researchers will know which drug they are being provided (open-label). Participants will visit the clinic 5 times over 6 weeks for checkups, blood tests and questionaries. The first two visits will be seven days apart and include the two doses of iron treatment.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Iron is essential for the normal functioning of a human body. Iron deficiency anemia (IDA) occurs when blood lacks adequate healthy red blood cells, preventing adequate distribution of oxygen throughout the tissue of the body.

IDA, if left uncorrected, may result in complications such as extreme fatigue, weakness, chest pain, shortness of breath, irregular heartbeats or even heart failure in some cases, in addition to reducing the overall quality of life of a patient. Iron supplementation can effectively treat IDA. An iron-rich diet is known to enhance iron levels, however supplementation is limited by the bio-availability of iron compounds. Oral iron treatment is the most common form of therapy for iron supplementation. However, oral iron supplementation is not ideal for all patients, as adverse events are common, and some patients also fail to respond. Common adverse events (AEs) include significant gastrointestinal discomfort, metallic taste and staining of teeth, resulting in patience discontinuing the treatment. Intravenous (i.v) iron therapy is regarded as a safe method to correct anemia resulting from several conditions that avoids many of the gastrointestinal AEs common with oral iron supplementation.

Ferric carboxymaltose is an established i.v iron formulation approved to treat IDA in Europe and USA. In patients with high iron need, ferric carboxymaltose requires at least two injections, at least 7 days apart. A new i.v. iron formulation has been developed, Ferric Bepectate IV Injection. Ferric Bepectate IV Injection has the potential to be dosed at higher volumes compared to other i.v. iron formulations, allowing for patients with high iron needs to only undergo a single infusion, reducing the medical burden on both the patient and the medical system, and providing a rapid improvement to IDA and associated symptoms.

The current phase 3 study aims to compare Ferric Bepectate IV Injection with two Ferric carboxymaltose formulations (comparators: Ferinject® and Injectafer®) to determine non-inferiority between the Ferric Bepectate IV Injection single dose administration and the current approved dosing for the comparators. A comparison between treatments of the change of hemoglobin (Hb) from baseline after 6 weeks will be the primary outcome. Safety of each treatment will also be assessed to determine superiority, by examining the number of adverse events in the 2 hour period following the beginning of infusion. Key secondary safety endpoints will assess the difference in volume-corrected urine iron after i.v administration, and incidence of hypophosphatemia during the 6 week follow-up period.

A two-dose administration of Ferric Bepectate IV Injection will also be assessed to compare efficacy, tolerance, and safety with the single-dose administration and the comparators.

Studietype

Intervensjonell

Registrering (Antatt)

1366

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Bulgaria
      • Sofia, Bulgaria
        • Medical Center Levitas EOOD
        • Hovedetterforsker:
          • Boris Krumov, MD
  • Forente stater
    • Florida
      • Coral Gables, Florida, Forente stater, 33146
        • Pharmasouth Research
        • Hovedetterforsker:
          • Francisco Quintana, MD
      • Melbourne, Florida, Forente stater, 32934
        • Trialmed Melbourne
        • Hovedetterforsker:
          • Murray A Kimmel, MD
      • The Villages, Florida, Forente stater, 32162
        • Trialmed The Villages
        • Hovedetterforsker:
          • Angela Okolie, MD
    • Texas
      • Dallas, Texas, Forente stater, 75246
        • M3 Wake Research
        • Hovedetterforsker:
          • Ralph Cox, MD
      • Houston, Texas, Forente stater, 77075
        • PatientCare Clinical Research
        • Hovedetterforsker:
          • Anibal Rossel, MD
      • San Antonio, Texas, Forente stater, 78229
        • Trialmed San Antonio
        • Hovedetterforsker:
          • Tahira Alves, MD
      • Sugar Land, Texas, Forente stater, 77478
        • Olympus Clinical Research
        • Hovedetterforsker:
          • Harish Thakker, MD
  • Polen
      • Skórzewo, Polen
        • Szpital AidPort
        • Hovedetterforsker:
          • Michal Kwiatek, MD
  • Romania
      • Bragadiru, Romania
        • Ames Medical Research
        • Hovedetterforsker:
          • Carastoian Nicoleta, MD
      • Bucharest, Romania
        • Colentina Clinical Hospital
        • Hovedetterforsker:
          • Daniela Georgescu, MD
      • Bucharest, Romania
        • Sana Medical Center
        • Hovedetterforsker:
          • Adrian Sarbu, MD
      • Cluj-Napoca, Romania
        • The Oncology Institute
        • Hovedetterforsker:
          • Ciprian Tomuleasa, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Male or female patient at least 18 years old at the time of screening
  2. Patients with general iron deficiency anaemia IDA
  3. Patients with serum ferritin levels ≤40 ng/mL inclusive
  4. Patients with haemoglobin (Hb) levels <10 g/dL
  5. Patients ≥ 35 kg body weight
  6. The patient has adequate hepatic and renal function defined as a serum aspartate aminotransferase or alanine aminotransferase level that are no more than 3 times the upper limit of the normal range, a serum bilirubin level that is no more than 2 times the upper limit of the normal range and a serum creatinine level of less than 2 mg/dL.
  7. The patient is able to understand the protocol and provides informed consent to participate in the study

Exclusion Criteria:

  1. Pregnant or breastfeeding patients
  2. Female patients not willing to use a safe method of contraception (PEARL index <1) for the full study (screening - V5).
  3. Severe physical inability, e.g., ASA physical status IV or V.
  4. Non-iron deficiency anaemia, e.g., known Vitamin B12 or folate deficiency, hemoglobinopathy, or unexplained anaemia.
  5. Patients with life-threatening anaemia, defined as Hb < 6.5 g/dL.
  6. Patient is expected to require a blood transfusion within the study period or has had a blood transfusion within the 30 days prior screening.
  7. Anticipated medical need for erythropoiesis-stimulating agents during the study period (screening - V5).
  8. Patients with hemodynamic instability due to any ongoing bleeding. Absence of ongoing bleeding will be confirmed either by decision of two independent physicians or by removal of drainage whichever occurs earlier in routine care.
  9. Patient has undergone a surgical procedure during the 30 days prior to screening, and/or is expected to undergo a surgical procedure during the study period (screening - V5).

  10. Patients with any contraindication to the investigational products, e.g.,

    1. known sensitivity to iron or an ingredient of the investigational products,
    2. significant history of systemic allergic reactions,
    3. hemochromatosis, thalassemia or TSAT >50% as indicator of iron overload,
    4. acute or chronic intoxication,
    5. infection (patient on non-prophylactic antibiotics),
    6. chronic liver disease and/or screening ALT or AST above three times the upper limit of the normal range.
    7. chronic kidney disease, defined as GFR <30 mL/min.
  11. Primary hematologic disease.
  12. Drug or alcohol abuse according to WHO definition.
  13. Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.
  14. Current or previous participation in another clinical trial during the last 90 days before screening.
  15. Exclusion criteria according to SmPC of Ferric Carboxymaltose.
  16. The following concomitant treatments prescribed by a physician for non-iron deficiency anaemia (e.g., known vitamin B12 or folate deficiency), hemoglobinopathy, or unexplained anaemia are not allowed during the study and 24 weeks before screening: Erythropoiesis-stimulating agents, vitamin B12, Folic acid or other I.V. or oral iron products.
  17. Estimated life expectancy of <6 months or, for cancer patients, an Eastern Cooperative Oncology Group performance status >1

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Ferric Bepectate IV Injection single dose (US/Japan)
Single dose experimental treatment arm for USA and Japan. 50 mg iron/mL. Up to 2000 mg per dose.
Legemiddel: Ferric Bepectate IV Injection
Ferric Bepectate IV Injection 50 mg iron/mL
Andre navn:
  • Feramyl
  • Ferric bepectate
Eksperimentell: Ferric Bepectate IV Injection single dose (RoW)
Single dose experimental treatment arm for rest of world. 50 mg iron/mL. Up to 2000 mg per dose.
Legemiddel: Ferric Bepectate IV Injection
Ferric Bepectate IV Injection 50 mg iron/mL
Andre navn:
  • Feramyl
  • Ferric bepectate
Eksperimentell: Ferric Bepectate IV Injection two doses (US/Japan)
Two dose experimental treatment arm for USA and Japan. 50 mg iron/mL. Up to 1000 mg per dose.
Legemiddel: Ferric Bepectate IV Injection
Ferric Bepectate IV Injection 50 mg iron/mL
Andre navn:
  • Feramyl
  • Ferric bepectate
Eksperimentell: Ferric Bepectate IV Injection two doses (RoW)
Two dose experimental treatment arm for rest of world. 50 mg iron/mL. Up to 1000 mg per dose.
Legemiddel: Ferric Bepectate IV Injection
Ferric Bepectate IV Injection 50 mg iron/mL
Andre navn:
  • Feramyl
  • Ferric bepectate
Aktiv komparator: Injectafer (US/Japan)
Two dose ferric carboxymaltose active comparator treatment for USA and Japan. 50 mg iron/mL. Up to 750 mg per dose.
Legemiddel: Ferric Carboxymaltose Injection [Injectafer®]
Ferric carboxymaltose (Injectafer®) 50 mg iron/mL in two doses 7-9 days apart
Andre navn:
  • Injectafer
Aktiv komparator: Ferinject (RoW)
Two dose ferric carboxymaltose active comparator treatment for rest of world. 50 mg iron/mL. Up to 1000 mg per dose.
Legemiddel: Ferric Carboxymaltose Injection [Ferinject]
Ferric carboxymaltose (Ferinject®) 50 mg iron/mL in two doses 7-9 days apart
Andre navn:
  • Ferinject

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in hemoglobin comparing one dose Ferric bepectate and two dose Injectafer treatment
Tidsramme: 6 weeks
The mean change in blood hemoglobin from baseline at week 6 showing non-inferiority between the treatment groups Ferric Bepectate IV Injection (single dose) and Injectafer
6 weeks
Change in hemoglobin comparing one dose Ferric bepectate and two dose Ferinject treatment
Tidsramme: 6 weeks
The mean change in blood hemoglobin from baseline at week 6 showing non-inferiority between the treatment groups Ferric Bepectate IV Injection (single dose) and Ferinject
6 weeks
Incidence of treatment emergent adverse events
Tidsramme: 2 hours post infusion start
Incidence of treatment emergent adverse events (TEAE) during the 2 hours following the start of infusion
2 hours post infusion start

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Blood hemoglobin amount
Tidsramme: 6 weeks
Mean blood hemoglobin at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
6 weeks
Hemoglobin change from baseline
Tidsramme: 6 weeks
Mean change in blood hemoglobin from baseline to weeks 1, 2, 4 and 6.
6 weeks
Serum iron change from baseline
Tidsramme: 6 weeks
Mean change in serum iron from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
6 weeks
Serum ferritin change from baseline
Tidsramme: 6 weeks
Mean change in serum ferritin from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
6 weeks
Serum transferrin change from baseline
Tidsramme: 6 weeks
Mean change in serum transferrin from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
6 weeks
Serum transferrin saturation change from baseline
Tidsramme: 6 weeks
Mean change in serum transferrin saturation (TSAT) from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.
6 weeks
Response Rate
Tidsramme: 6 weeks
Proportion of patients with normalization (defined in WHO classification) of hemoglobin at week 6 (Response Rate).
6 weeks
Time to normalization of hemoglobin
Tidsramme: 6 weeks
Time to normalization normalization (defined in WHO classification) of hemoglobin at week 6 (Response Rate).
6 weeks
Incidence of hypophosphatemia
Tidsramme: 6 weeks
Incidence of hypophosphatemia (serum phosphate < 2 mg/dL) at any time during the follow-up period (baseline - week 6)
6 weeks
Volume-corrected urine iron amount
Tidsramme: 2 hours
Pre- and post-difference of volume-corrected urine iron levels measured before and in the first urine after the end of i.v. administration, (volume corrected iron urine is defined as the ratio between urine iron and urine creatinine)
2 hours
Adverse event severity
Tidsramme: 2 hours following infusion start
Severity of treatment emergent adverse events (TEAEs) during the 2 hours following infusion start
2 hours following infusion start
Adverse event incidence and severity
Tidsramme: 6 weeks
Incidence and severity of TEAEs during the entire study period (screening - V5)
6 weeks
Treatment related adverse event incidence and severity
Tidsramme: 6 weeks
Incidence and severity of AEs classified as possibly, probably or definitely related to the study drug (Treatment related adverse events; TRAE) during the study period (screening - V5)
6 weeks
Incidence of injection/infusion site reactions and hypersensitivity reactions
Tidsramme: 2 hours following infusion start
Incidence of injection/infusion site reactions and hypersensitivity reactions
2 hours following infusion start
Change in serum phosphate
Tidsramme: 6 weeks
Mean change in serum phosphate from baseline to week 6
6 weeks
Change in serum calcium
Tidsramme: 6 weeks
Mean change in serum calcium from baseline to week 6
6 weeks
ECG changes
Tidsramme: 6 weeks

Electrocardiogram (ECG) changes from baseline at week 1, 2, 4 and 6. The ECG will specifically assess the following parameters:

  • Heart Rate
  • QT interval
  • ST depression
  • T wave inversion
  • Prescence of tachycardia
  • Left ventricular hypertrophy
  • Investigator interpretation (normal, abnormal NCS, abnormal CS)
6 weeks
ECG and Hemoglobin relationship
Tidsramme: 6 weeks
Relation between electrocardiogram (ECG) investigator interpretation (normal, abnormal NCS, abnormal CS) and hemoglobin at baseline and End of Treatment
6 weeks
Change in fatigue symptoms
Tidsramme: 6 weeks
Change in fatigue symptoms from baseline at week 6 measured by the Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue). A final score of 0-52 is calculated, where a high score indicates better quality of life.
6 weeks

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pooled data hemoglobin amount
Tidsramme: 6 weeks
Mean hemoglobin at weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
6 weeks
Pooled data change in hemoglobin
Tidsramme: 6 weeks
Mean change in hemoglobin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
6 weeks
Pooled data change in serum iron
Tidsramme: 6 weeks
Mean change in serum iron from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
6 weeks
Pooled data change in serum ferritin
Tidsramme: 6 weeks
Mean change in serum ferritin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
6 weeks
Pooled data change in serum transferrin
Tidsramme: 6 weeks
Mean change in serum transferrin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
6 weeks
Pooled data change in serum transferrin saturation
Tidsramme: 6 weeks
Mean change in serum transferrin saturation (TSAT) from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.
6 weeks
Proportion of patients requiring blood transfusion
Tidsramme: 6 weeks
Proportion of patients who require red blood cell transfusion up to week 6. Pooled data (USA+Japan+RoW) between study regions.
6 weeks
Duration of hospital stay
Tidsramme: 6 weeks
Duration of hospital stay (days), if applicable. Pooled data (USA+Japan+RoW) between study regions.
6 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

AFT Pharmaceuticals, Ltd.

Samarbeidspartnere

HungaroTrial

Etterforskere

  • Studieleder: Ioana Stanescu, Phil.Lic., MSc., AFT Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. juni 2028

Studiet fullført (Antatt)

1. juli 2028

Datoer for studieregistrering

Først innsendt

30. juni 2026

Først innsendt som oppfylte QC-kriteriene

30. juni 2026

Først lagt ut (Faktiske)

7. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • AFT-FERA-01
  • 2026-527543-17-00 (Ctis)
  • U1111-1343-1640 (Registeridentifikator: UTN)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

The results of the study may be published in a scientific journal, however individual patient data will not be used, rather data will be provided as descriptive statistics (mean, median, IQR) as required.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere